ema retatrutide approval Trial of next-gen weight-loss drug brings it one step closer to FDA Why Retatrutide Is Gaining Attention

DPP-4i was selected as the active comparator given its documented cardiovascular neutrality, whereas sodium-glucose cotransporter-2 inhibitors were not used as a comparator due to their established cardiovascular benefits

Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P

For large-scale preparation, continuous synthesis technology using microfluidic chips (e.g., microchannel reactors) can significantly improve the yield and reduce costs, enabling the mass production of nanoparticles [11, 281]

Moreover, inheritance of IL1R2 rs11886877 AA variant and the TLR4 rs10759932 variant is associated with a slightly increased PC risk